This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

IFNB Multiple Sclerosis Study Group trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This was a multicentre, blinded, randomised, placebo-controlled trial of interferon beta-1b in patients with mild relapsing-remitting multiple sclerosis.

372 patients were recruited:

  • mean age 35.5 years
  • ambulatory
  • mild disability (EDSS scores 0 - 5.5)
  • short duration of definite MS (mean duration 4.4 years)
  • duration of follow-up 3.5 to 5 years

The treatment arms consisted of:

  • low dose - 1.6 MIU subcutaneously alternate days
  • high dose - 8 MIU subcutaneously alternate days

The end-points were:

  • relapse frequency
  • disease burden on T2-weighted MRI scans of the brain
  • confirmed disease progression

Reference:

  • 1) The IFNB multiple sclerosis study group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis-I: clinical results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655-61
  • 2) The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-85

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.